You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

ERYTHROMYCIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Erythromycin, and what generic alternatives are available?

Erythromycin is a drug marketed by Azurity, Barr, Encube, Fougera Pharms, Padagis Us, Elkins Sinn, Bausch And Lomb, Pharmaderm, Pharmafair, Sentiss, Paddock Llc, Alpharma Us Pharms, Bausch, Lilly, Pai Holdings Pharm, Pharmobedient Cnsltg, Renaissance Pharma, Epic Pharma Llc, Norvium Bioscience, Amneal Pharms Co, Torrent, Alembic, Alkem Labs Ltd, Cadila Pharms Ltd, Teva Pharms Usa Inc, Zydus Lifesciences, Zydus Pharms, Rising, Ivax Sub Teva Pharms, Watson Labs, Cosette, Life Labs, Amneal Pharms, Ani Pharms, Endo Operations, Dista, Naska, Parke Davis, Aurobindo Pharma Usa, Abraxis Pharm, Baxter Hlthcare, Exela Pharma, Nexus, Teva Parenteral, Lederle, and Purepac Pharm. and is included in seventy-six NDAs.

The generic ingredient in ERYTHROMYCIN is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ERYTHROMYCIN?
  • What are the global sales for ERYTHROMYCIN?
  • What is Average Wholesale Price for ERYTHROMYCIN?
Drug patent expirations by year for ERYTHROMYCIN
Drug Prices for ERYTHROMYCIN

See drug prices for ERYTHROMYCIN

Drug Sales Revenue Trends for ERYTHROMYCIN

See drug sales revenues for ERYTHROMYCIN

Recent Clinical Trials for ERYTHROMYCIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
TakedaPhase 1
Chang Gung Memorial HospitalPhase 1/Phase 2
Assiut UniversityN/A

See all ERYTHROMYCIN clinical trials

Pharmacology for ERYTHROMYCIN
Medical Subject Heading (MeSH) Categories for ERYTHROMYCIN

US Patents and Regulatory Information for ERYTHROMYCIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cadila Pharms Ltd ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate GRANULE;ORAL 216212-001 Nov 21, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lederle ERYTHROMYCIN STEARATE erythromycin stearate TABLET;ORAL 062089-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alkem Labs Ltd ERYTHROMYCIN erythromycin TABLET;ORAL 216066-002 Jul 13, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amneal Pharms Co ERYTHROMYCIN erythromycin TABLET, DELAYED RELEASE;ORAL 210954-001 Jul 2, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.